Nothing new presented, we can expect an income stream from the newly approved product Bronchitol first half next year and the CEO was pretty upbeat about LOXL2 trial for Phase 2 next year and he appeared to be confident that the open ended trial will come up with positive results. It will however take some time before we can have another FDA approved product I reckon.
Ann: Ceasing to be a substantial holder from Arix Bioscience, page-70
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
